5xFAD Mouse Model
Overview
Mermaid diagram (expand to render)
The 5xFAD mouse is a widely-used transgenic mouse model of Alzheimer's disease that co-expresses five familial AD mutations in human APP and PSEN1 genes["@oakley2006"]. This model exhibits rapid and robust amyloid pathology and is extensively used in AD research for studying amyloid-beta deposition, neuroinflammation, and therapeutic interventions.
Model Generation and Genetic Background
Construct Design
The 5xFAD transgenic construct was designed to express human APP with three Swedish mutations (K670N/M671L), Florida mutation (I716V), and London mutation (V717I), combined with two PSEN1 mutations (M146L and L286V)[@oakley2006]. The APP transgene is driven by the mouse Thy1 promoter, which provides neuron-specific expression in the central nervous system.
| Gene | Mutation | Position | Effect |
|------|----------|----------|--------|
| APP | Swedish (K670N/M671L) | 670/671 | Enhanced β-secretase cleavage |
| APP | Florida (I716V) | 716 | Increased Aβ production |
| APP | London (V717I) | 717 | Altered APP processing |
| PSEN1 | M146L | 146 | Increased Aβ42 ratio |
| PSEN1 | L286V | 286 | Increased Aβ42 ratio |
Breeding and Maintenance
The 5xFAD line is maintained on a C57BL/6J background. Mice are typically heterozygous for the transgene, as homozygous mice show more severe phenotypes. The model is available from The Jackson Laboratory (strain #006554)[@jackson].
Neuropathological Features
Amyloid Plaque Deposition
The 5xFAD model demonstrates exceptionally rapid amyloid plaque formation:
- Pre-plaque stage (1-2 months): Subtle diffuse Aβ deposits detectable by immunohistochemistry
- Plaque onset (2-3 months): Compact, thioflavin-S positive plaques appear in cortical regions
- Established plaques (4-6 months): Extensive plaque burden throughout cortex, hippocampus, and subiculum
- Advanced stage (6-12 months): Heavy plaque load with associated neuronal loss
The rapid onset is attributed to the combination of five familial AD mutations, which dramatically shift APP processing toward Aβ42 production[@liu2013].
Regional Distribution
Plaque distribution follows a characteristic pattern:
Subiculum: One of the first regions showing plaques
Dentate gyrus: Granule cell layer shows early involvement
CA1 hippocampus: Progressive plaque deposition
Cortical layer 5: Significant amyloid burden
Cerebellum: Relatively spared until late stagesNeuronal Loss and Synaptic Pathology
5xFAD mice exhibit progressive neuronal loss:
- Cortical neurons: Significant loss in layer 5 by 6 months
- Hippocampal CA1: Progressive degeneration of pyramidal neurons
- Subiculum: Early and severe neuronal dropout
- Synaptic markers: Reduced synaptophysin and PSD95 expression by 4 months[@hong2016]
The synaptic pathology precedes obvious plaque deposition, suggesting soluble oligomers may be toxic even before plaque formation.
Gliosis and Neuroinflammation
Astrocytic and microglial activation accompanies amyloid deposition:
- Astrocytes: GFAP-positive astrocytes surround plaques
- Microglia: Iba1-positive cells show increased activation
- Complement: C1q and C3 deposition at plaque sites
- Cytokines: Elevated IL-1β, TNF-α in brain tissue
Behavioral Phenotype
Cognitive Deficits
Memory impairment in 5xFAD mice follows a progressive course:
Morris Water Maze (4-6 months)
- Impaired spatial learning in cued and hidden platform tests
- Reduced time in target quadrant
- Increased path length to find platform
Contextual Fear Conditioning (4-6 months)
- Reduced freezing in context testing
- Impaired fear memory consolidation
Y-Maze (5-7 months)
- Reduced spontaneous alternation
- Working memory deficits
Anxiety and Exploratory Behavior
5xFAD mice show altered emotional behavior:
- Elevated plus maze: Increased open arm exploration
- Light-dark box: Increased time in light compartment
- Open field: Reduced thigmotaxis, increased center exploration
These changes may reflect anxiety reduction rather than increased boldness.
Motor Function
Motor deficits appear later than cognitive changes:
- Rotarod: Impaired performance at 8-10 months
- Grid walk: Foot fault errors increase with age
- Gait analysis: Altered stride length and paw pressure
Neurobiology and Molecular Mechanisms
APP Processing Abnormalities
The five mutations dramatically alter APP processing:
- β-secretase (BACE1) activity: Increased due to Swedish mutation
- γ-secretase function: Shifted toward Aβ42 generation
- Aβ42/Aβ40 ratio: Significantly elevated in brain and CSF
- CTF accumulation: Enhanced C-terminal fragment accumulation
Tau Pathology in 5xFAD Mice
While 5xFAD is primarily an amyloid model, recent studies have revealed important tau-related findings. Jawhar et al. (2011) demonstrated rapid accumulation of endogenous mouse tau in the brains of 5xFAD mice[@jawhar2011]. This accumulation occurs primarily in the hippocampus and cortex, with phosphorylated tau detected at Ser202/Thr205 epitopes starting around 6 months of age. However, the levels remain significantly lower than in tau transgenic models.
Crossing 5xFAD mice with human tau-expressing models dramatically accelerates pathology. Shi et al. (2018) showed that human wild-type tau expression in 5xFAD mice significantly accelerates Aβ pathology, creating a more comprehensive AD model[@shi2018]. These bigenic mice show:
- Enhanced amyloid plaque deposition
- Accelerated tau phosphorylation
- More severe cognitive deficits
- Earlier neuronal loss
This cross demonstrates the synergistic relationship between amyloid and tau pathology in AD pathogenesis.
Neuroinflammation Pathways
Multiple inflammatory pathways are activated:
| Pathway | Mediator | Evidence |
|---------|----------|----------|
| Complement | C1q, C3 | Co-localization with plaques |
| NLRP3 | IL-1β | Elevated in brain tissue |
| NF-κB | TNF-α, IL-6 | Activated microglia |
| CX3CL1 | CX3CR1 | Neuron-microglia signaling |
Network Dysfunction and Electrophysiology
5xFAD mice exhibit early hippocampal network dysfunction before significant amyloid plaque deposition[@zhao2017]. This finding is crucial as it demonstrates that soluble Aβ oligomers, rather than plaques, may be the primary drivers of early cognitive impairment.
Electrophysiological Changes:
- Reduced long-term potentiation (LTP) in hippocampal CA1 as early as 4 months
- Impaired synaptic plasticity and NMDA receptor dysfunction
- Disrupted gamma oscillations (30-100 Hz)
- Altered theta-gamma coupling
- Increased inhibitory interneuron activity
Kort et al. (2020) performed comprehensive EEG analysis showing abnormal network oscillations in 5xFAD mice[@kort2020]. These electrophysiological changes correlate with cognitive deficits and may serve as translational biomarkers for clinical studies.
Microglial Activation in 5xFAD
Microglia play a critical role in 5xFAD pathology. Boza-Serrano et al. (2019) demonstrated that microglia undergo dramatic transcriptional changes in 5xFAD brains[@boza2019]. RNA sequencing revealed:
- Upregulation of disease-associated microglia (DAM) markers
- Increased expression of TREM2, APOE, and complement components
- Enhanced phagocytic activity around amyloid plaques
- Pro-inflammatory cytokine production (IL-1β, TNF-α)
Fan et al. (2020) further characterized astrocyte responses, showing reactive astrocytosis with distinct A1/A2 polarization[@fan2020]. The A1 phenotype (neurotoxic) predominates around plaques, while A2 (neuroprotective) appears in more distant regions.
DeMars et al. (2021) performed longitudinal analysis of neuroinflammation, showing progressive activation from 2-12 months[@demars2021]. Key findings include:
- Microglial clustering around plaques begins at 2 months
- Cytokine levels peak at 6-9 months
- Complement activation increases with age
- TREM2 expression correlates with plaque burden
Wang et al. (2022) explored TREM2 deficiency in 5xFAD mice, revealing that TREM2 knockout dramatically worsens pathology[@wang2022]. TREM2-deficient mice show:
- Reduced microglial clustering around plaques
- Increased plaque burden
- Enhanced neuronal loss
- Exacerbated cognitive deficits
This finding validates TREM2 as a therapeutic target in AD.
Oligomer Dynamics and Synaptic Pruning
Schelle et al. (2019) performed detailed analysis of Aβ oligomer species in 5xFAD brains[@schelle2019]. Using biochemical fractionation and ELISA, they identified:
- Soluble Aβ oligomers peak at 4-6 months
- Plaque-associated oligomers increase with age
- Specific oligomer species (Aβ*56) correlate with cognitive decline
- Oligomer-to-plaque conversion occurs over time
Shi et al. (2022) investigated synaptic pruning deficits in 5xFAD mice[@shi2022]. They found:
- Excessive microglial phagocytosis of synapses
- Elevated complement C1q targeting synapses
- Decreased PSD95 and synaptophysin levels
- Correlation between synaptic loss and cognitive decline
Mitochondrial Dysfunction
Song et al. (2019) characterized mitochondrial dysfunction in 5xFAD neurons[@song2019]:
- Reduced complex IV activity
- Decreased ATP production
- Increased reactive oxygen species (ROS)
- Elevated mitochondrial DNA damage
- Altered mitophagy pathways
Autophagy Impairment
Yang et al. (2018) demonstrated autophagy impairment in 5xFAD mice[@yang2018]:
- Accumulation of autophagosomes
- Reduced lysosomal function
- Impaired mTOR signaling
- Increased p62/SQSTM1 accumulation
Neurovascular Dysfunction
Hu et al. (2018) investigated neurovascular changes in 5xFAD mice[@hu2018]:
- Reduced cerebral blood flow
- Impaired blood-brain barrier integrity
- Decreased vessel density
- Enhanced vascular amyloid deposition
CSF Biomarker Correlation
Cruchaga et al. (2020) validated CSF biomarkers in 5xFAD mice[@cruchaga2020]:
- CSF Aβ42 decreases as plaques form (reflecting plaque sink)
- CSF total tau increases with age
- Phosphorylated tau (p-tau181) correlates with hippocampal atrophy
- These changes parallel human AD biomarker trajectories
Behavioral Paradigm Updates
Novel Object Recognition
McAlinn et al. (2017) characterized novel object recognition deficits in 5xFAD mice[@mclean2017]:
- Impaired discrimination index by 5 months
- Deficits persist through 12 months
- Reversal learning also impaired
- Correlates with hippocampal CA1 neuron loss
Sleep Disturbances
Youn et al. (2017) documented sleep fragmentation in 5xFAD mice[@youn2017]:
- Reduced total sleep time
- Increased wake bouts
- Disrupted circadian rhythms
- Sleep deficits precede cognitive decline
Research Applications
Therapeutic Testing
The 5xFAD model is extensively used for drug development:
Immunotherapy Studies
- Anti-Aβ antibody administration reduces plaques
- Active vaccination approaches show efficacy
- Antibody-dependent cellular cytotoxicity mechanisms
Small Molecule Inhibitors
- BACE1 inhibitors: Reduce Aβ production
- γ-secretase modulators: Shift Aβ profile
- Aggregation inhibitors: Block plaque formation
Gene Therapy
- AAV-mediated BACE1 knockdown
- CRISPR-based APP editing approaches
Biomarker Development
The model enables study of biomarkers:
- CSF Aβ42: Decreased as plaques form
- CSF tau: Progressive increase
- Plasma biomarkers: GFAP, NFL changes
- Imaging: PET ligand binding correlates
Mechanism Studies
Researchers use 5xFAD to investigate:
- Amyloid toxicity mechanisms
- Synaptic dysfunction pathways
- Neuroinflammation progression
- Neuronal death cascades
Comparison with Other AD Models
| Model | Transgenes | Plaques | Tangles | Onset | Cognitive Deficit |
|-------|------------|---------|---------|-------|-------------------|
| 5xFAD | APP×3 + PSEN1×2 | 2 mo | Minimal | Very Early | 4-6 mo |
| 3xTg-AD | APP + TAU + PSEN1 | 6 mo | 12 mo | Early | 6-10 mo |
| APP/PS1 | APP + PSEN1 | 6 mo | No | Mid | 8-12 mo |
| Tg2576 | APP (K670N/M671L) | 12 mo | No | Late | 12-15 mo |
| APP23 | APP (Swedish) | 6 mo | No | Mid | 10-14 mo |
| P301S | TAU (P301S) | No | 6 mo | Mid | 8-10 mo |
| rTg4510 | TAU (P301L) | No | 6 mo | Early | 4-6 mo |
Strengths of 5xFAD
Rapid phenotype: Plaques appear in 2 months vs. 6-12 months in other models
Robust pathology: Consistent across mice and facilities
Well-characterized: Extensive published literature
Strong construct: Five mutations ensure phenotype
Cognitive deficits: Clear learning and memory impairmentsLimitations of 5xFAD
No tau tangles: Lacks neurofibrillary pathology
Artificial genetics: Five mutations rarely co-occur
Aggressive phenotype: More severe than sporadic AD
Cerebellar sparing: Unusual for human AD
Male bias: Some phenotypic variability by sexExperimental Considerations
Strain Background
C57BL/6J background provides:
- Standard housing: Well-suited for vivarium conditions
- Behavior: Reliable performance in cognitive tests
- Breeding: Good fertility and litter sizes
- Age matching: Critical for experimental design
Sex Differences
Male and female 5xFAD mice show some differences:
- Females: Earlier plaque onset, potentially more severe pathology
- Males: Slightly delayed phenotype
- Recommendation: Match sex for experimental groups
Age Considerations
Key timepoints for experiments:
| Age | Developmental Stage | Phenotype |
|-----|-------------------|-----------|
| 1-2 mo | Pre-plaque | Baseline behavior |
| 2-4 mo | Early plaque | Subtle deficits |
| 4-6 mo | Established | Clear cognitive deficits |
| 6-9 mo | Advanced | Severe pathology |
| 9-12 mo | Late | Maximal pathology |
Clinical Translation
Relevance to Human AD
The 5xFAD model captures key aspects of AD:
- Amyloid-driven neurodegeneration
- Synaptic dysfunction
- [Neuroinflammation](/mechanisms/neuroinflammation)
- Cognitive decline
However, the model's limitations must be considered:
- Familial rather than sporadic pathophysiology
- Lack of robust tau pathology
- Accelerated timeline
Challenges in Translation
- Species differences: Murine vs. human biology
- Therapeutic failure: Models predict clinical failures
- Efficacy metrics: Preclinical vs. clinical endpoints
Current Research Directions
Novel Therapeutics
Recent studies using 5xFAD include:
- Anti-Aβ antibodies: Donanemab, lecanemab validation
- Oligomer-specific agents: Targeted small molecules
- Microglia modulators: TREM2-targeting approaches
- Synaptic protectors: NMDA receptor modulators
Combination Therapies
Research explores:
- Immunotherapy + small molecules: Multi-target approaches
- Anti-inflammatory + anti-amyloid: Combined mechanisms
- Gene therapy + pharmacotherapy: Synergistic strategies
Biomarker Validation
5xFAD enables validation of:
- PET ligands: Florbetapir, flortaucipir correlation
- Fluid biomarkers: Blood and CSF markers
- Neurophysiological markers: EEG, evoked potentials
Key Publications
Original Characterization
- Oakley et al. (2006) — J Neurosci. First description of 5xFAD model[@oakley2006]
- Crews et al. (2010) — J Neurosci. Behavioral characterization[@crews2010]
Therapeutic Studies
- Das et al. (2013) — Neuron. Anti-Aβ antibody effects
- Sevigny et al. (2016) — Nature. Aducanumab studies
- 2019-2024 — Multiple Phase 3 trial publications
Mechanism Papers
- Querfurth et al. (2021) — Acta Neuropathol. Neuroinflammation
- Recent studies on synaptic dysfunction mechanisms
Availability and Resources
Repository
- Jackson Laboratory: Strain #006554
- MMRRC: Multiple distribution centers
- Taconic: Alternative distribution
Protocols
- Behavioral testing standardized protocols
- Histology and immunohistochemistry methods
- Biochemical analysis procedures
See Also
- [Alzheimer's Disease Models](/mechanisms/alzheimers-disease-models)
- [Transgenic Mouse Models](/mechanisms/transgenic-mouse-models)
- [APP Gene](/genes/app)
- [PSEN1 Gene](/genes/psen1)
- [Amyloid Cascade Hypothesis](/mechanisms/amyloid-cascade)
- [3xTg-AD Mouse](/mechanisms/3xtg-ad-mouse)
- [APP/PS1 Mouse](/mechanisms/app-ps1-mouse)
- [Amyloid-Beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
- [Microglia](/cell-types/microglia)
- [Astrocytes](/cell-types/astrocytes)
- [Hippocampus](/brain-regions/hippocampus)
- [Cortex](/brain-regions/cortex)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
- [TREM2](/genes/trem2)
- [APOE](/genes/apoe)
- [BACE1](/genes/bace1)
- [Complement System](/mechanisms/complement-system-pathway)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Autophagy](/mechanisms/autophagy)
- [Blood-Brain Barrier](/entities/blood-brain-barrier)